LataMed AI Corp. (OTC: LMED), a development-stage digital health and artificial intelligence technology company, today announced continued advancement of its mobile healthcare application ecosystem, including applications being prepared for anticipated future availability through both the Apple App Store and Google Play Store. The company also revealed that early-stage platform subscribers have surpassed 1,000, a milestone management believes reflects growing engagement with its healthcare technology platform.
The applications under development are intended to support telehealth, healthcare communication, patient engagement, provider coordination, emergency response, and AI-assisted healthcare initiatives as part of LataMed AI’s broader digital healthcare infrastructure strategy. Management stated that the company is continuing development, testing, integration, and platform optimization efforts for multiple mobile healthcare applications targeting emerging markets, particularly Latin America. Certain applications are presently being prepared for anticipated future submission to Apple and Google platforms following continued development, internal testing, platform review processes, and applicable regulatory considerations.
Dr. Kevin Rodan Levy, Chief Executive Officer of LataMed AI Corp., stated: “We are continuing to advance development of our mobile healthcare application ecosystem with the goal of expanding accessibility and healthcare connectivity through both Apple and Android mobile platforms. Surpassing 1,000 early-stage users represents an encouraging milestone as we continue refining and expanding our broader digital healthcare infrastructure initiatives.”
The company believes continued onboarding activity and user engagement may provide valuable operational feedback as development efforts progress and additional platform functionality is evaluated and refined. LataMed AI noted that its broader technology initiatives remain focused on scalable healthcare infrastructure solutions intended to support underserved and developing markets where access to healthcare coordination, telehealth services, and digital healthcare tools may be limited or fragmented.
The company emphasized that the applications and related platform technologies remain under active development and have not yet been fully commercialized or broadly deployed. No assurance can be provided regarding the timing of any public release, App Store or Google Play availability, regulatory progression, commercialization initiatives, future platform functionality, or operational success of the applications or related technologies.
For more information, please visit https://latamed.ai or review the Company’s filings with the U.S. Securities and Exchange Commission at www.sec.gov.
